Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
ChiCTR2500113324Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: 2-year post-recurrence overall survival. Started Nov 2025; status: recruiting.
02
Drugs
sintilimabcamrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500113324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113324.